Background: The presence of pulmonary right-to-left shunting (RLS) is associated with severe neurological complications from paradoxical embolisation in patients with hereditary haemorrhagic telangiectasia (HHT) and screening is warranted. Pulmonary shunt fraction measurement with the 100% oxygen method can be used for the detection and quantification of functional pulmonary RLS, although transthoracic contrast echocardiography (TTCE) has emerged as the gold standard over the last few years. Objective: The aim of this study was to determine the true diagnostic accuracy of the established 100% oxygen method in detecting pulmonary RLS, as compared to TTCE. Methods: We analysed 628 persons screened for HHT between 2004 and 2010, all of whom underwent TTCE. A quantitative 3-point grading scale was used to differentiate between minimal, moderate or extensive pulmonary RLS on TTCE (grade 1-3, respectively). Additional shunt fraction measurement with the 100% oxygen method was pursued in cases of pO2 <13 or <12 kPa in patients younger or older than 30 years, respectively. A shunt fraction >5% was considered pathological. Results: Both TTCE and the 100% oxygen method were performed in 210 subjects. Although the presence of a pathological shunt fraction correlated with an increased pulmonary shunt grade on TTCE, the 100% oxygen method confirmed a >5% shunt fraction in only 51% of patients with pulmonary RLS on TTCE (14, 20 and 72% for grade 1, 2 and 3, respectively). Conclusion: Pulmonary shunt fraction measurement with the 100% oxygen method is not a useful screening technique for the detection of pulmonary RLS in HHT as its sensitivity is too low and large pulmonary shunts on TTCE may remain undetected using this method.

Keywords:
Pulmonary right-to-left shunting, Transthoracic contrast echocardiography, 100% oxygen method, Hereditary haemorrhagic telangiectasia, Shunt fraction measurement
1.
Begbie ME, Wallace GM, Shovlin CL: Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003;79:18-24.
2.
Velthuis S, Buscarini E, van Gent MW, Gazzaniga P, Manfredi G, Danesino C, et al: Grade of pulmonary right-to-left shunt on contrast echocardiography and cerebral complications: a striking association. Chest 2013;144:542-548.
3.
Gossage JR, Kanj G: Pulmonary arteriovenous malformations: a state of the art review. Am J Respir Crit Care Med 1998;158:643-661.
4.
Mager JJ, Overtoom TT, Blauw H, Lammers JW, Westermann CJ: Embolotherapy of pulmonary arteriovenous malformations: long-term results in 112 patients. J Vasc Interv Radiol 2004;15:451-456.
5.
Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, et al: The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997;61:60-67.
6.
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al: Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351.
7.
Velthuis S, Buscarini E, Mager JJ, Vorselaars VM, van Gent MW, Gazzaniga P, et al: Predicting the size of pulmonary arteriovenous malformations on chest computed tomography: a role for transthoracic contrast echocardiography. Eur Respir J 2014;44:150-159.
8.
Cottin V, Dupuis-Girod S, Lesca G, Cordier JF: Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration 2007;74:361-378.
9.
Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al: International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48:73-87.
10.
Gallitelli M, Guastamacchia E, Resta F, Guanti G, Sabba C: Pulmonary arteriovenous malformations, hereditary hemorrhagic telangiectasia, and brain abscess. Respiration 2006;73:553-557.
11.
van Gent MW, Post MC, Luermans JG, Snijder RJ, Westermann CJ, Plokker HW, et al: Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study. Eur Respir J 2009;33:85-91.
12.
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-67.
13.
Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, et al: Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 2005;116:8-16.
14.
Chiang ST: Anomogram for venous shunt (Qs-Qt) calculation. Thorax 1968;23:563-565.
15.
Mager JJ, Zanen P, Verzijlbergen F, Westermann CJ, Haitjema T, van Herk G, et al: Quantification of right-to-left shunt with 99mTc-labelled albumin macroaggregates and 100% oxygen in patients with hereditary haemorrhagic telangiectasia. Clin Sci (Lond) 2002;102:127-134.
16.
van Gent MW, Post MC, Snijder RJ, Swaans MJ, Plokker HW, Westermann CJ, et al: Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy? Chest 2009;135:1288-1292.
17.
van Gent MW, Post MC, Snijder RJ, Westermann CJ, Plokker HW, Mager JJ: Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010;138:833-839.
18.
Gazzaniga P, Buscarini E, Leandro G, Reduzzi L, Grosso M, Pongiglione G, et al: Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter? Eur J Echocardiogr 2009;10:513-518.
19.
Soliman OI, Geleijnse ML, Meijboom FJ, Nemes A, Kamp O, Nihoyannopoulos P, et al: The use of contrast echocardiography for the detection of cardiac shunts. Eur J Echocardiogr 2007;8:S2-S12.
20.
Chilvers ER, Whyte MK, Jackson JE, Allison DJ, Hughes JM: Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations. Am Rev Respir Dis 1990;142:420-425.
21.
Haitjema TJ, Overtoom TT, Westermann CJ, Lammers JW: Embolisation of pulmonary arteriovenous malformations: results and follow up in 32 patients. Thorax 1995;50:719-723.
22.
Hartnell GG, Jackson JE, Allison DJ: Coil embolization of pulmonary arteriovenous malformations. Cardiovasc Intervent Radiol 1990;13:347-350.
23.
Jackson JE, Whyte MK, Allison DJ, Hughes JM: Coil embolization of pulmonary arteriovenous malformations. Cor Vasa 1990;32:191-196.
24.
Pennington DW, Gold WM, Gordon RL, Steiger D, Ring EJ, Golden JA: Treatment of pulmonary arteriovenous malformations by therapeutic embolization: rest and exercise physiology in eight patients. Am Rev Respir Dis 1992;145:1047-1051.
25.
Terry PB, White RIJ, Barth KH, Kaufman SL, Mitchell SE: Pulmonary arteriovenous malformations: physiologic observations and results of therapeutic balloon embolization. N Engl J Med 1983;308:1197-1200.
26.
Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF: Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004;169:994-1000.
27.
Bommer WJ, Shah PM, Allen H, Meltzer R, Kisslo J: The safety of contrast echocardiography: report of the Committee on Contrast Echocardiography for the American Society of Echocardiography. J Am Coll Cardiol 1984;3:6-13.
28.
Gossage JR: The role of echocardiography in screening for pulmonary arteriovenous malformations. Chest 2003;123:320-322.
29.
Nanthakumar K, Graham AT, Robinson TI, Grande P, Pugash RA, Clarke JA, et al: Contrast echocardiography for detection of pulmonary arteriovenous malformations. Am Heart J 2001;141:243-246.
30.
Velthuis S, Vorselaars VM, van Gent MW, Westermann CJ, Snijder RJ, Mager JJ, et al: Role of transthoracic contrast echocardiography in the clinical diagnosis of hereditary hemorrhagic telangiectasia. Chest 2013;144:1876-1882.
31.
Wagner PD, Laravuso RB, Uhl RR, West JB: Continuous distributions of ventilation-perfusion ratios in normal subjects breathing air and 100 per cent O2. J Clin Invest 1974;54:54-68.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.